The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
All press releases
Regulatory press releases
Non-regulatory press releases
2020
2023
2022
2021
2019
2018
2017
2016
2015
2013
All years
November 25, 2020
Promore Pharma participates at “Aktiespararna’s Stora Aktiedagen”
November 24, 2020
Interim report January – September 2020
November 20, 2020
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2020
November 20, 2020
Clarification of outcome in the clinical trial HEAL LL-37
November 19, 2020
Promore Pharma announces positive results from Phase IIb study of ropocamptide in the treatment of venous leg ulcers
October 27, 2020
Nomination Committee Appointed for the Annual General Meeting 2021 in Promore Pharma
August 25, 2020
Promore Pharma AB (publ) Interim report January – June 2020
August 19, 2020
Invitation to Presentation of Promore Pharma’s Interim Report for the Second Quarter 2020
July 14, 2020
Promore Pharma is Granted a Patent for ropocamptide in the US
May 28, 2020
Promore Pharma Appoints Erik Magnusson as Chief Financial Officer
May 26, 2020
Report from the Annual General Meeting of Promore Pharma AB held on 26 May 2020
May 26, 2020
Promore Pharma AB (publ) Interim report January – March 2020
May 25, 2020
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2020
May 5, 2020
Promore Pharma’s Annual Report 2019 Published
April 22, 2020
Notice of Annual General Meeting in Promore Pharma AB (publ)
April 2, 2020
Promore Pharma´s CFO leaves the company in 2020
March 24, 2020
Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial
February 18, 2020
Promore Pharma AB (publ) Year-end report 2019
February 13, 2020
Invitation to Presentation of Promore Pharma’s Year-end report for 2019
